Australia’s primary health regulator is reviewing the safety of a common herbal ingredient found in numerous over-the-counter cold and flu remedies. The Therapeutic Goods Administration (TGA) is currently evaluating reports of severe, life-threatening allergic reactions linked to Andrographis paniculata, a plant extract widely marketed for its ability to reduce the duration and severity of upper respiratory infections.
The move comes after multiple reports of anaphylaxis—a systemic and potentially fatal allergic response—were associated with the consumption of supplements containing the herb. Since these products are often viewed as “natural” and are available without a prescription, many consumers may be unaware of the potential for severe adverse reactions, leading the TGA to consider action on widely used flu supplements to ensure public safety.
As a physician, I have seen a growing trend of patients integrating traditional herbal medicines into their healthcare routines. Even as these treatments can offer supportive care, the assumption that “natural” equates to “safe” is a dangerous misconception. Anaphylaxis is a medical emergency that requires immediate intervention, and the current investigation highlights the critical need for rigorous oversight of the complementary medicine sector.
The clinical risk of Andrographis paniculata
Andrographis paniculata, often referred to as “King of Bitters,” has been used for centuries in Ayurvedic and Traditional Chinese Medicine to treat fevers and respiratory ailments. In modern Australian pharmacies, it is a staple in various “immune support” and “flu relief” formulations. However, the TGA’s current probe centers on the ingredient’s potential to trigger an extreme immune response in susceptible individuals.
Anaphylaxis occurs when the immune system overreacts to a trigger, releasing a flood of chemicals that can cause the throat to swell, blood pressure to drop sharply, and the respiratory system to fail. For a consumer reaching for a natural remedy to treat a mild cold, the sudden onset of such a reaction can be catastrophic, especially if they are alone or unaware of the trigger.
The regulator is specifically examining the frequency and severity of these events to determine if the current labeling and safety warnings are sufficient. The goal is to establish whether the risks associated with the herb outweigh its therapeutic benefits for the general population, or if specific contraindications must be mandated on all packaging.
| Reaction Level | Common Symptoms | Urgency |
|---|---|---|
| Mild to Moderate | Hives, itching, swelling of the lips or face, nausea | Consult a pharmacist or GP |
| Severe (Anaphylaxis) | Difficulty breathing, swelling of the throat, rapid/weak pulse, dizziness | Immediate Emergency Call (000) |
| Systemic Shock | Loss of consciousness, profound drop in blood pressure | Critical Emergency Intervention |
Regulatory pathways and potential outcomes
When the TGA identifies a safety signal—such as a cluster of adverse event reports—it initiates a formal review process. This involves analyzing clinical data, reviewing the manufacturer’s safety profiles, and assessing the prevalence of the ingredient across the market. The outcomes of such reviews generally fall into a few specific categories of regulatory action.
The regulator may first mandate updated warning labels, explicitly alerting consumers to the risk of anaphylaxis. In more severe cases, the TGA can move to “schedule” the ingredient, which would restrict its sale to pharmacy-only or prescription-only status, ensuring a healthcare professional screens the patient for allergies before use.
If the evidence suggests the risk is too high for the general public, the TGA has the authority to order the recall of specific products or ban the use of the ingredient in over-the-counter supplements entirely. This process ensures that the Therapeutic Goods Administration maintains a balanced risk-benefit ratio for all medicines sold in Australia.
What consumers should know
For those currently using cold and flu supplements, the most important step is to check the ingredient list for Andrographis paniculata. If you have a history of severe allergies or asthma, you should exercise increased caution when introducing new herbal supplements into your regimen.
It is also vital to recognize that herbal products can interact with other medications. For instance, ingredients that affect the immune system or blood clotting may interfere with prescription drugs, making medical supervision essential. Patients should be encouraged to maintain a comprehensive list of all supplements they are taking and share this with their primary care provider.
If a person experiences any of the following symptoms after taking a supplement, they should seek immediate medical attention:
- Sudden swelling of the tongue, lips, or throat
- Tightness in the chest or wheezing
- A sudden drop in blood pressure resulting in fainting or dizziness
- Widespread hives or a rapid, itching rash
The broader impact on natural health products
This investigation reflects a broader global shift toward stricter regulation of the “nutraceutical” industry. For too long, herbal supplements have operated in a regulatory grey area, with less stringent testing than conventional pharmaceuticals. As these products turn into more potent and widely available, the potential for adverse drug-herb interactions and severe allergic reactions increases.
The TGA’s proactive stance serves as a reminder that the safety profile of a plant-based medicine is not static. Environmental factors, sourcing methods, and the concentration of active compounds can vary between brands, potentially altering the safety of the final product. By treating these supplements with the same scrutiny as synthetic drugs, the regulator is prioritizing patient safety over market convenience.
Consumers who suspect they have had an adverse reaction to a supplement are encouraged to report it via the TGA reporting portal. These reports are the primary mechanism the government uses to identify dangerous trends and trigger the safety reviews that protect the public.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment.
The TGA is expected to provide further updates as it concludes its evidence review and determines whether formal changes to the listing or scheduling of Andrographis paniculata are required. We will continue to monitor the regulator’s announcements regarding product recalls or labeling mandates.
Do you use herbal supplements for cold and flu relief? Share your experiences in the comments or let us know if you have questions about supplement safety.
